Preclinical evidence demonstrated the potential efficacy of combining uprosertib with MEKi against a range of cancer cell lines with mutations in the BRAF or KRAS genes (NCT01935973, NCT01989598) (Dumble et al., 2014). The gene discussed is BRAF; the disease is cancer.